Blockchain Registration Transaction Record

NRx Pharma Gets FDA Nod for Phase 2/3 Trial of NRX-101 in Suicidal Depression

NRx Pharmaceuticals receives FDA clearance for Phase 2/3 trial of NRX-101 in treatment-resistant major depressive disorder with suicidality, enrolling 240 participants across academic and military sites.

This trial is significant because it addresses the urgent need for effective treatments in patients with treatment-resistant major depressive disorder and suicidality, a population at high risk. If successful, NRX-101 could offer a new therapeutic option that combines oral medication with transcranial magnetic stimulation, potentially reducing suicide rates and improving quality of life. The FDA's clearance also validates NRx's NMDA platform, paving the way for further innovation in CNS disorders.